vs
Arcellx, Inc.（ACLX）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
Arcellx, Inc.的季度营收约是Aligos Therapeutics, Inc.的9.8倍（$1.7M vs $169.0K）。Arcellx, Inc.净利率更高（-3513.4% vs -11763.9%，领先8250.5%）。Aligos Therapeutics, Inc.同比增速更快（-72.1% vs -89.2%）。过去两年Aligos Therapeutics, Inc.的营收复合增速更高（-50.7% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
ACLX vs ALGS — 直观对比
营收规模更大
ACLX
是对方的9.8倍
$169.0K
营收增速更快
ALGS
高出17.1%
-89.2%
净利率更高
ACLX
高出8250.5%
-11763.9%
两年增速更快
ALGS
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $169.0K |
| 净利润 | $-58.1M | $-19.9M |
| 毛利率 | — | — |
| 营业利润率 | -3850.2% | -12907.7% |
| 净利率 | -3513.4% | -11763.9% |
| 营收同比 | -89.2% | -72.1% |
| 净利润同比 | -23.4% | 75.8% |
| 每股收益（稀释后） | $-1.01 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXALGS
| Q4 25 | $1.7M | $169.0K | ||
| Q3 25 | $4.9M | $741.0K | ||
| Q2 25 | $7.6M | $965.0K | ||
| Q1 25 | $8.1M | $311.0K | ||
| Q4 24 | $15.3M | $606.0K | ||
| Q3 24 | $26.0M | $1.3M | ||
| Q2 24 | $27.4M | $1.1M | ||
| Q1 24 | $39.3M | $694.0K |
净利润ACLXALGS
| Q4 25 | $-58.1M | $-19.9M | ||
| Q3 25 | $-55.8M | $-31.5M | ||
| Q2 25 | $-52.8M | $-15.9M | ||
| Q1 25 | $-62.3M | $43.1M | ||
| Q4 24 | $-47.1M | $-82.2M | ||
| Q3 24 | $-25.9M | $-19.3M | ||
| Q2 24 | $-27.2M | $5.1M | ||
| Q1 24 | $-7.2M | $-34.9M |
营业利润率ACLXALGS
| Q4 25 | -3850.2% | -12907.7% | ||
| Q3 25 | -1248.3% | -3827.4% | ||
| Q2 25 | -777.4% | -1924.0% | ||
| Q1 25 | -847.6% | -6187.5% | ||
| Q4 24 | -348.2% | -3393.2% | ||
| Q3 24 | -129.1% | -1610.5% | ||
| Q2 24 | -127.8% | -2489.5% | ||
| Q1 24 | -40.3% | -3176.7% |
净利率ACLXALGS
| Q4 25 | -3513.4% | -11763.9% | ||
| Q3 25 | -1127.1% | -4256.0% | ||
| Q2 25 | -698.6% | -1643.8% | ||
| Q1 25 | -766.0% | 13854.7% | ||
| Q4 24 | -308.4% | -13556.1% | ||
| Q3 24 | -99.4% | -1540.7% | ||
| Q2 24 | -99.3% | 477.0% | ||
| Q1 24 | -18.3% | -5023.5% |
每股收益（稀释后）ACLXALGS
| Q4 25 | $-1.01 | $4.23 | ||
| Q3 25 | $-0.99 | $-3.04 | ||
| Q2 25 | $-0.94 | $-1.53 | ||
| Q1 25 | $-1.13 | $-2.11 | ||
| Q4 24 | $-0.87 | $-13.10 | ||
| Q3 24 | $-0.48 | $-3.07 | ||
| Q2 24 | $-0.51 | $0.81 | ||
| Q1 24 | $-0.14 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $77.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $402.4M | $53.5M |
| 总资产 | $604.0M | $88.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXALGS
| Q4 25 | $450.3M | $77.8M | ||
| Q3 25 | $461.4M | $99.1M | ||
| Q2 25 | $453.1M | $122.9M | ||
| Q1 25 | $543.3M | $137.9M | ||
| Q4 24 | $587.4M | $56.9M | ||
| Q3 24 | $574.3M | $74.9M | ||
| Q2 24 | $516.7M | $94.5M | ||
| Q1 24 | $573.9M | $112.7M |
股东权益ACLXALGS
| Q4 25 | $402.4M | $53.5M | ||
| Q3 25 | $440.8M | $71.8M | ||
| Q2 25 | $392.2M | $101.9M | ||
| Q1 25 | $416.9M | $116.4M | ||
| Q4 24 | $454.8M | $-29.0M | ||
| Q3 24 | $483.0M | $50.1M | ||
| Q2 24 | $487.2M | $67.2M | ||
| Q1 24 | $496.6M | $59.8M |
总资产ACLXALGS
| Q4 25 | $604.0M | $88.5M | ||
| Q3 25 | $655.9M | $109.8M | ||
| Q2 25 | $619.1M | $134.7M | ||
| Q1 25 | $648.1M | $150.7M | ||
| Q4 24 | $711.3M | $70.1M | ||
| Q3 24 | $764.9M | $88.4M | ||
| Q2 24 | $734.3M | $108.8M | ||
| Q1 24 | $779.7M | $127.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXALGS
| Q4 25 | $-58.2M | $-21.7M | ||
| Q3 25 | $-49.2M | $-24.3M | ||
| Q2 25 | $-39.7M | $-15.5M | ||
| Q1 25 | $-63.1M | $-20.9M | ||
| Q4 24 | $-46.0M | $-18.4M | ||
| Q3 24 | $30.7M | $-20.1M | ||
| Q2 24 | $-36.2M | $-19.5M | ||
| Q1 24 | $-31.9M | $-22.7M |
自由现金流ACLXALGS
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
自由现金流率ACLXALGS
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
资本支出强度ACLXALGS
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
现金转化率ACLXALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
